

Pr Karin TARTE Directrice UR1
Pr Thierry FEST Directeur Adjoint UR1

Céline BENOIST – Gestionnaire UR1 – CDD
Céline LEPINE – Gestionnaire INSERM
Céline MONVOISIN – Assistant Prévention (20 %)
Yoni DESVOIS – Adjoint Tech UR1
Laurent DELEURME – Tech UR1 – 50%
Simon LEONARD – Chair UR1 – 50 %

SCIENTIFIC ADVISORY BOARD
Eric SOLARY (IGR Paris)
Pierre BROUSSET (CRCT Toulouse)
Dominique BONNET (F Crick Institute London)

Research axes

Research Group 1
Axis 1 : Normal, Tumoral B-cell Differentiation & Environmental Cues
PI : Pr Thierry FEST

| | |
|---------------------------------------|----------------------------------------|
| Olivier DECAUX PU-PH UR1 | Céline DELALOY CR1 INSERM |
| Gersende CARON LACOMBE Ing CHU | Fabrice CHATONNET Ing CHU |
| Fabienne DESMOTS LOYER Ing CHU | Céline PANGAULT MCU-PH UR1 |
| Maud LEMARIE Post Doc INSERM | Alexis GRASSEAU Post Doc INSERM |
| Céline NONN Tech CHU | Marine LOUARN PhD INSERM |
| Kathleen SANTAMARIA PhD UR1 | Juliette GAUTHIER PhD UR1 |

Research Group 2
Axis 2 : Lymphoid microenvironment in Health and Disease
PI : Pr Karin TARTE

| | |
|-----------------------------------------|----------------------------------------|
| Patricia AME-THOMAS MCU-PH UR1 | Frédéric MOURCIN CR EFS |
| David ROULOIS CR2 INSERM | Elise DESSAUGE Ing INSERM |
| Vonick SIBUT Ing INSERM CDD | Ansie MARTIN Post Doc INSERM |
| Ilenia PAPA Post Doc INSERM | Florent CREUSAT Post doc INSERM |
| Francine PADONOU Post Doc INSERM | Marion GUIRRIEC , AI INSERM 60% |
| Céline MONVOISIN AI UR1 | Rachel JEAN Tech CHU |
| Florence JOUAN Tech UR1 | Claire LAMAISON PhD UR1 |
| Marvin SYLVESTRE PhD UR1 | Juliette FERRANT PhD UR1 |
| Tony MARCHAND PhD UR1 | Baptiste BRAUGE PhD UR1 |

Translational Research axes

SITI (CHU - EFS) - Karin TARTE Director

CORE LAB :

Cédric MENARD MCU-PH UR1
Delphine ROSSILLE Ing CHU

Mikaël ROUSSEL PH CHU / Contrat d'interface INSERM
Nadège BESCHER Tech CHU

Joëlle DULONG Ing EFS
Maëlle LATOUR Tech CHU

Simon LE GALLOU Ing CHU
Clodilde VERDY Tech CHU CDD

Axis 1 : Blood biomarkers of lymphoma diagnosis and prognosis : impact of new anti-tumoral treatments

| | |
|-------------------------------------|----------------------------------|
| Karin TARTE PU-PH UR1 | Thierry FEST PU-PH UR1 |
| Thierry LAMY PU-PH UR1 | Mikaël ROUSSEL PH CHU |
| Roch HOUOT PU-PH UR1 | Simon LE GALLOU Ing CHU |
| Cédric MENARD MCU-PH UR1 | Delphine ROSSILLE Ing CHU |
| Cédric PASTORET AHU, PhD CHU | Simon BOUZY AHU, CHU |

Axis 3 : Myeloid suppressive cells in sepsis

| | |
|----------------------------------|--------------------------------------|
| Jean-Marc TADIE PU-PH UR1 | Murielle GREGOIRE Ing CHU |
| Yves LE TULZO PU-PH UR1 | Mathieu LESOUHAITIER PhD, CHU |

Axis 4 : Antibody engineering

| | |
|-------------------------------|-----------------------------|
| Michel COGNE PU-PH | Gilbert SEMANA PU-PH |
| Yannick DANGER Ing EFS | Natsuko UEDA PhD UR1 |

Axis 2 : Immunosuppressive properties of mesenchymal stromal cells : mechanisms and clinical applications

| | |
|-------------------------------------|-------------------------------------|
| Éric WATIER PU-PH UR1 | Séverine LOISEL Ing EFS |
| Karin TARTE PU-PH UR1 | Isabelle BEZIER Tech CHU CDD |
| Nicolas BERTHEUIL MCU-PH UR1 | Erwan DUMONTET AHU, PhD UR1 |
| Marie CORNIC Tech EFS | |

Axis 5 : Inflammation

| | |
|-----------------------------------|----------------------------------|
| Patricia AME THOMAS MCU-PH | Laure MICHEL MCU PH |
| Charlotte LUCAS CCA | Marion MANDON Ing CHU CDD |